Benefits
FODMAP digestive support (fructan-specific)
Fructans are a specific FODMAP class commonly shared across many fruits and vegetables — including wheat, onions, garlic, asparagus, artichokes, and chicory root. Fructanase breaks down fructans into shorter fructose chains and free sugars that are more easily absorbed in the small intestine — preventing colonic fermentation that causes bloating, gas, and abdominal discomfort in FODMAP-sensitive individuals.
Phase I safety and tolerability validated
Phase I safety and tolerability validated: a randomized double-blind placebo-controlled trial evaluating 2,000 INU/day found the fructanase preparation safe and well tolerated, with no significant differences in GI outcomes vs placebo. Foundational safety established for regulatory and consumer applications.
FDA NDIN-granted regulatory status
Optiziome® Fructanase is one of only six fungal/microbial enzymes in the past decade to receive FDA New Dietary Ingredient Notification (NDIN). NDIN status requires demonstration of safety under recommended conditions of use — provides regulatory clarity for finished product manufacturers. Safety dossier reviewed by GRAS associates (SGS Nutrasource) for FDA compliance.
IBS and FODMAP sensitivity applications
Researchers noted further research is warranted to assess whether microbial inulinase supplementation can reduce fructan malabsorption, GI symptoms, and intestinal inflammation in individuals with FODMAP sensitivity and IBS — perhaps in combination with other FODMAP-targeting enzymes such as α-galactosidase. Future applications expanding from healthy adults to symptomatic populations.
Healthy food enabler — eat more fruits and vegetables
Fructanase makes hard-to-digest but healthy fruits and vegetables (onions, garlic, asparagus, artichokes, wheat) more accessible to FODMAP-sensitive individuals. Strict FODMAP elimination diets are nutritionally restrictive — fructanase supports broader dietary variety while managing symptoms. Positions as healthy-food enabler vs symptom-management-only.
Non-genetically modified, wild-type enzyme
BIO-CAT's fructanase is a non-genetically modified, wild-type enzyme preparation — supporting clean-label and non-GMO positioning. Many enzyme manufacturers use genetically modified production strains for higher yield; BIO-CAT's wild-type approach addresses consumer concerns about GMO-derived ingredients while maintaining quality and activity.
Combination potential with α-galactosidase
Researchers explicitly noted combination potential with α-galactosidase (the enzyme in BeanO® for galactan FODMAP digestion). Combined fructan + galactan digestion would address two of the major FODMAP classes. Supports formulation potential for comprehensive FODMAP-targeting enzyme blends.
Mechanism of action
Fructan glycosidic bond cleavage
Fructanase enzymes cleave the β-2,1 and β-2,6 glycosidic bonds in fructans — breaking the polysaccharide chains into shorter fructo-oligosaccharides and free fructose. The shorter products are more readily absorbed in the small intestine or less fermentable in the colon. Mechanism directly addresses the cause of fructan-induced GI discomfort.
Inulin (long-chain fructan) digestion
Inulin is a specific long-chain fructan with chicory root as a primary source. Often added as 'prebiotic fiber' to supplements and functional foods. Inulin/fructans are well-intentioned but problematic for FODMAP-sensitive individuals. Fructanase breaks down inulin alongside dietary fructans.
Reduced colonic fermentation
Undigested fructans pass into the colon where they're fermented by gut bacteria — producing gas (CO2, hydrogen, methane) and short-chain fatty acids. While SCFAs are beneficial, the gas production causes bloating, distension, and discomfort in sensitive individuals. Pre-digestion via fructanase reduces fermentation substrate reaching the colon.
Stomach and small intestine activity
Fructanase remains active in the stomach (acid-tolerant) and small intestine — providing fructan digestion at multiple GI locations. The activity range matches where dietary fructans are typically encountered. Resilience to gastric pH and intestinal conditions enables effective oral enzyme therapy.
Clinical trials
Randomized double-blind placebo-controlled Phase I clinical trial evaluating Optiziome Fructanase at 2,000 INU/day (400 mg capsule twice daily) vs placebo over 4 weeks. Foundational safety study. Managed by SGS Nutrasource (Canada). Published in Gastro Hep Advances.
60 healthy male and female participants aged 20-65 with no diagnosed GI issues. 4-week intervention.
Fructanase at 2,000 INU/day was safe and well tolerated, with no significant differences in GI outcomes vs placebo. The researchers noted that the trial included healthy adults — differences in symptoms would not be expected since baseline GI symptoms were minimal. Foundation for the FDA NDIN. Future trials needed in FODMAP-sensitive and IBS populations to demonstrate efficacy.
Comprehensive safety dossier supporting FDA New Dietary Ingredient Notification (NDIN) for Optiziome® Fructanase. Reviewed by GRAS associates (SGS Nutrasource) for FDA compliance. One of only six fungal/microbial enzymes to achieve NDIN status in the past decade.
Not applicable — comprehensive safety review for regulatory submission.
Safety dossier provided evidence supporting fructanase safety under recommended conditions of use. FDA accepted the NDIN — indicating regulatory acceptance of safety profile. The regulatory milestone supports finished product manufacturer confidence and provides legal pathway for product launch in the US dietary supplement market.